| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Agenus Inc. | AgenT-797 | Refractory (2L+) gastric cancer, refractory gastroesophageal cancer (GEC) | Phase 2 | Data Released | Intravenous | Oncology |
| Agenus Inc. | Neoadjuvant BOT/BAL - (NEOASIS) | Early-Stage Solid Tumors | Phase 2 | Data Released | Intravesical | Oncology |
| Agenus Inc. | Neoadjuvant botensilimab plus balstilimab - (NEST-1) | Colorectal cancer | Phase 2 | Data Released | Intravenous | Oncology |
| Agenus Inc. | Balstilimab | Advanced/metastatic non-melanoma skin cancers (Agenonmela) | Phase 2 | Ongoing | Intravenous | Oncology |
| Agenus Inc. | Botensilimab - (ACTIVATE) | Advanced MSS Colorectal Cancer and Advanced Melanoma | BLA Filing | Data Released | Intravenous | Oncology |
| Agenus Inc. | Balstilimab | Cervical cancer | BLA Filing | Withdrawn | Intravenous | Oncology |
| Agenus Inc. | AGEN1423 with Balstilimab | Pancreatic Cancer | Phase 2 | Ongoing | Intravenous | Oncology |
| Agenus Inc. | AGEN1423 | Advanced pancreatic cancer | Phase 2 | Ongoing | Intravenous | Oncology |